Company: RVRC
Filing Date: 2025-08-13
Form Type: S-1/A
Source: 0001213900-25-075747
Chunk: 186

Company: Revium Rx.
Filing Date: 2025-08-13
Form: S-1/A
Chunk 186
---
’s business and operations and
on Israel’s economy in general.

On June 13,
2025, in light of continued nuclear threats and intelligence assessments indicating imminent attacks, Israel launched a pre-emptive strike
directly targeting military and nuclear infrastructure inside Iran aimed to disrupt Iran’s capacity to coordinate or launch further
hostilities against Israel, as well as disrupt its nuclear program. On June 25, 2025, a ceasefire between Israel and Iran took effect.
Nonetheless, hostilities between Israel and Iran may resume and further escalate, with both sides launching attacks against one another.
Company’s subsidiaries experienced disruptions to their work during such period. Since June 25, 2025, The Company’s subsidiaries have
been returning to full activity together with its local vendors and consultants. The Company doesn’t expect a material adverse effect
on its business.

The Company
continues to monitor its ongoing activities and will make adjustments in its business if needed, including updating any estimates or judgments
impacting its financial statements as appropriate.

NOTE 2 – SIGNIFICANT ACCOUNTING POLICIES

Following the
closing of the Share Exchange agreement with Lipovation on July 23, 2024, in accordance with ASC 810, Lipovation’s financial statement
are presented as the “Predecessor” for periods prior to the closing of the acquisition. Revium Rx, which includes consolidation
of Lipovation Ltd subsequent to the acquisition, is the “Successor” for periods after the closing of the Business Combination.
As a result of the application of the acquisition method of accounting in the Successor period, the financial statements for the Successor
period are presented on a full step-up basis as a result of the acquisition and are therefore not comparable to the financial statements
of the Predecessor period that are not presented on the same full step-up basis.

<div align='center'>F-9</div>

REVIUM RX.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands

NOTE 2 – SIGNIFICANT ACCOUNTING POLICIES (Cont.)

Successor

The consolidated
Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S.
GAAP”).

| a. | Use of estimates in preparation of Financial Statements: |

The preparation
of consolidated Financial Statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions
that affect the amounts reported in the consolidated Financial Statements and accompanying notes. The Company evaluates